You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 022560

✉ Email this page to a colleague

NDA 022560 describes ATELVIA, which is a drug marketed by Apil and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ATELVIA profile page.

The generic ingredient in ATELVIA is risedronate sodium. There are nineteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the risedronate sodium profile page.

Summary for 022560

Tradename:	ATELVIA
Applicant:	Apil
Ingredient:	risedronate sodium
Patents:	3

Pharmacology for NDA: 022560

Medical Subject Heading (MeSH) Categories for 022560

Bone Density Conservation Agents
Calcium Channel Blockers

Suppliers and Packaging for NDA: 022560

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ATELVIA	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	022560	NDA	Allergan, Inc.	0430-0979	0430-0979-03	4 TABLET, DELAYED RELEASE in 1 DOSE PACK (0430-0979-03)
ATELVIA	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	022560	NDA AUTHORIZED GENERIC	Greenstone LLC	59762-0407	59762-0407-4	1 BLISTER PACK in 1 CARTON (59762-0407-4) / 4 TABLET, DELAYED RELEASE in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, DELAYED RELEASE;ORAL			Strength	35MG
Approval Date:	Oct 8, 2010	TE:	AB	RLD:	Yes
Patent:	⤷ Get Started Free	Patent Expiration:	Jan 9, 2028	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
Patent:	⤷ Get Started Free	Patent Expiration:	Jan 9, 2028	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
Patent:	⤷ Get Started Free	Patent Expiration:	Jan 16, 2026	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 022560

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apil	ATELVIA	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	022560-001	Oct 8, 2010	⤷ Get Started Free	⤷ Get Started Free
Apil	ATELVIA	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	022560-001	Oct 8, 2010	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.